Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials)

American Journal of Cardiology

Volumn 114, Issue 5, 2014, Pages 711-715

  Gaudet, Daniel ^a   Kereiakes, Dean J ^b   McKenney, James M ^c   Roth, Eli M ^d   Hanotin, Corinne ^e   Gipe, Daniel ^f   Du, Yunling ^f   Ferrand, Anne Catherine ^e   Ginsberg, Henry N ^g   Stein, Evan A ^h  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b The Carl & Edyth Lindner Center for Research & Education   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d Sterling Research Group   (United States)

^e SANOFI   (France)

^f REGENERON PHARMACEUTICALS INC   (United States)

^g Och Spine at New York Presbyterian Hospitals   (United States)

^h Metabolic and Atherosclerotic Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES, MONOCLONAL; CHOLIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEIN(A); MALE; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; PYRROLES; STEROID METABOLISM, INBORN ERRORS; SUBTILISIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84908363070     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2014.05.060     Document Type: Article

References (30)